There is no obvious similarity in chemical structure among all of these substances, but they have in common the ability to stimulate the pentose phosphate pathway in red blood cells, which must mean that they are able to oxidize NADPH directly or indirectly
This dual-receptor pharmacology, GH release through GHSR1a and cardioprotection through CD36, gives GHRP-6 a therapeutic profile that newer, more selective secretagogues like ipamorelin do not possess
Almost nothing else in common
For example, in breast cancer, KCNMA1, KCNJ3, KCNN4, and KCNK9 are associated with estrogen receptor expression and lymph node and brain metastases
These include hypertension, diabetes, smoking, obesity, and a history of dyslipidemia